Annual SGA
$71.67 M
-$7.63 M-9.62%
December 31, 2023
Summary
- As of February 7, 2025, ALLO annual SGA is $71.67 million, with the most recent change of -$7.63 million (-9.62%) on December 31, 2023.
- During the last 3 years, ALLO annual SGA has risen by +$6.42 million (+9.83%).
- ALLO annual SGA is now -9.62% below its all-time high of $79.31 million, reached on December 31, 2022.
Performance
ALLO SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$16.33 M
+$246.00 K+1.53%
September 30, 2024
Summary
- As of February 7, 2025, ALLO quarterly SGA is $16.33 million, with the most recent change of +$246.00 thousand (+1.53%) on September 30, 2024.
- Over the past year, ALLO quarterly SGA has dropped by -$708.00 thousand (-4.15%).
- ALLO quarterly SGA is now -22.23% below its all-time high of $21.00 million, reached on December 31, 2022.
Performance
ALLO Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$6.64 B
-$285.90 M-4.50%
September 30, 2024
Summary
- As of February 7, 2025, ALLO TTM SGA is -$6.64 billion, with the most recent change of -$285.90 million (-4.50%) on September 30, 2024.
- Over the past year, ALLO TTM SGA has dropped by -$6.72 billion (-8904.31%).
- ALLO TTM SGA is now -4730.46% below its all-time high of -$137.52 million.
Performance
ALLO TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
ALLO Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.6% | -4.2% | -8904.3% |
| 3 y3 years | +9.8% | -16.3% | -8576.8% |
| 5 y5 years | +74.9% | +8.8% | -10000.0% |
ALLO Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -9.6% | at low | -22.2% | +1.5% | -110.7% | at low |
| 5 y | 5-year | -9.6% | +24.7% | -22.2% | +7.4% | -427.8% | at low |
| alltime | all time | -9.6% | +74.9% | -22.2% | +528.9% | -4730.5% | at low |
Allogene Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $16.33 M(+1.5%) | $66.91 M(-1.0%) |
| Jun 2024 | - | $16.09 M(-6.8%) | $67.62 M(-3.5%) |
| Mar 2024 | - | $17.27 M(+0.2%) | $70.06 M(-2.3%) |
| Dec 2023 | $71.67 M(-9.6%) | $17.22 M(+1.1%) | $71.67 M(-5.0%) |
| Sep 2023 | - | $17.04 M(-8.0%) | $75.45 M(-2.4%) |
| Jun 2023 | - | $18.52 M(-1.9%) | $77.31 M(-1.3%) |
| Mar 2023 | - | $18.88 M(-10.1%) | $78.29 M(-1.3%) |
| Dec 2022 | $79.31 M(+7.0%) | $21.00 M(+11.1%) | $79.31 M(+1.3%) |
| Sep 2022 | - | $18.90 M(-3.1%) | $78.26 M(-0.1%) |
| Jun 2022 | - | $19.51 M(-2.0%) | $78.37 M(+0.9%) |
| Mar 2022 | - | $19.90 M(-0.3%) | $77.64 M(+4.8%) |
| Dec 2021 | $74.11 M | $19.96 M(+5.1%) | $74.11 M(+4.0%) |
| Sep 2021 | - | $19.00 M(+1.1%) | $71.28 M(+3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | $18.78 M(+14.8%) | $68.90 M(+4.4%) |
| Mar 2021 | - | $16.36 M(-4.5%) | $65.98 M(+1.1%) |
| Dec 2020 | $65.26 M(+13.5%) | $17.13 M(+3.1%) | $65.26 M(+3.0%) |
| Sep 2020 | - | $16.62 M(+4.8%) | $63.33 M(+2.6%) |
| Jun 2020 | - | $15.86 M(+1.4%) | $61.73 M(+2.8%) |
| Mar 2020 | - | $15.64 M(+2.8%) | $60.06 M(+4.5%) |
| Dec 2019 | $57.47 M(+40.2%) | $15.21 M(+1.3%) | $57.47 M(+1.2%) |
| Sep 2019 | - | $15.02 M(+5.8%) | $56.80 M(+7.0%) |
| Jun 2019 | - | $14.19 M(+8.6%) | $53.10 M(+3.2%) |
| Mar 2019 | - | $13.06 M(-10.2%) | $51.44 M(+25.5%) |
| Dec 2018 | $40.98 M | $14.54 M(+28.5%) | $40.98 M(+55.0%) |
| Sep 2018 | - | $11.32 M(-9.7%) | $26.44 M(+74.8%) |
| Jun 2018 | - | $12.53 M(+382.3%) | $15.12 M(+482.3%) |
| Mar 2018 | - | $2.60 M | $2.60 M |
FAQ
- What is Allogene Therapeutics annual SGA?
- What is the all time high annual SGA for Allogene Therapeutics?
- What is Allogene Therapeutics annual SGA year-on-year change?
- What is Allogene Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Allogene Therapeutics?
- What is Allogene Therapeutics quarterly SGA year-on-year change?
- What is Allogene Therapeutics TTM SGA?
- What is the all time high TTM SGA for Allogene Therapeutics?
- What is Allogene Therapeutics TTM SGA year-on-year change?
What is Allogene Therapeutics annual SGA?
The current annual SGA of ALLO is $71.67 M
What is the all time high annual SGA for Allogene Therapeutics?
Allogene Therapeutics all-time high annual SGA is $79.31 M
What is Allogene Therapeutics annual SGA year-on-year change?
Over the past year, ALLO annual SGA has changed by -$7.63 M (-9.62%)
What is Allogene Therapeutics quarterly SGA?
The current quarterly SGA of ALLO is $16.33 M
What is the all time high quarterly SGA for Allogene Therapeutics?
Allogene Therapeutics all-time high quarterly SGA is $21.00 M
What is Allogene Therapeutics quarterly SGA year-on-year change?
Over the past year, ALLO quarterly SGA has changed by -$708.00 K (-4.15%)
What is Allogene Therapeutics TTM SGA?
The current TTM SGA of ALLO is -$6.64 B
What is the all time high TTM SGA for Allogene Therapeutics?
Allogene Therapeutics all-time high TTM SGA is -$137.52 M
What is Allogene Therapeutics TTM SGA year-on-year change?
Over the past year, ALLO TTM SGA has changed by -$6.72 B (-8904.31%)